Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome

被引:40
|
作者
Rogolino, A
Coccia, ME
Fedi, S
Gori, AM
Cellai, AP
Scarselli, GF
Prisco, D
Abbate, R
机构
[1] Univ Florence, Azienda Osped Careggi, Thrombosis Ctr, Dept Med & Surg Crit Care, I-50121 Florence, Italy
[2] Univ Florence, Dept Obstet & Gynecol, I-50121 Florence, Italy
关键词
coagulation; fibrinolysis; severe ovarian hyperstimulation syndrome; tissue factor; tissue factor pathway inhibitor;
D O I
10.1097/00001721-200304000-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During ovarian gonadotrophin stimulation for ovulation induction or in vitro fertilization, a clinical severe ovarian hyperstimulation syndrome (OHSS) may occur. Only few studies have investigated the mechanism responsible for the alterations of the haemostatic system in women affected by severe OHSS. The aim of the present study was to investigate the correlation between the magnitude of ovarian stimulation and the increase in fibrin formation and degradation in severe OHSS. Twenty-five patients (age range 23-43 years) who were hospitalized for severe OHSS, 25 women undergoing in vitro fertilization who did not develop OHSS (case-control group) and 25 healthy age-matched women (healthy control group) were investigated. On the day of admission a number of haemostatic markers, including D-dimer, thrombin-antithrombin complexes (TAT), prothrombin fragment 1 + 2 (F1 + 2), plasmin-antiplasmin complexes (PAP), tissue factor (TF), tissue factor pathway inhibitor (TFPI) and von Willebrand factor antigen (vWF), were examined. In patients with severe OHSS, TF, D-dimer, TAT, F1 + 2, PAP and vWF antigen plasma levels were significantly higher than those observed both in the case-control group and in healthy controls, whereas TFPI levels were significantly lower (P < 0.005) with respect to both case-controls and healthy controls. D-Dimer levels were related with serum oestradiol levels and oocyte number recovered (r = 0.45, P < 0.001 and r = 0.47, P < 0.001, respectively). D-Dimer and TAT levels were significantly (P < 0.05 and P < 0.005, respectively) higher in OHSS patients with unsuccessful pregnancy outcome (D-dimer, 226.5, 56-1449 ng/ml; TAT, 19.8, 3.1-82.6 mug/l) with respect to those with successful outcome of pregnancy (D-dimer, 145, 29-330 ng/ml; TAT, 5.0,1.0-19.6 mug/l). Our data indicate that a marked hypercoagulability with alterations of TF and TFPI levels is detectable in patients with severe OHSS and that it is related to the clinical outcome. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 50 条
  • [31] MEASUREMENT OF FUNCTIONAL AND IMMUNOLOGICAL LEVELS OF TISSUE FACTOR PATHWAY INHIBITOR - SOME METHODOLOGIC CONSIDERATIONS
    JESKE, W
    HOPPENSTEADT, D
    FAREED, J
    BERMES, E
    BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 : S73 - S80
  • [32] Serum levels of tissue factor pathway inhibitor: Potential association with Raynaud's phenomenon and telangiectasia in patients with systemic sclerosis
    Norimatsu, Yuta
    Miyagawa, Takuya
    Fukui, Yuki
    Omatsu, Jun
    Toyama, Satoshi
    Awaji, Kentaro
    Ikawa, Tetsuya
    Watanabe, Yusuke
    Yoshizaki, Ayumi
    Sato, Shinichi
    Asano, Yoshihide
    JOURNAL OF DERMATOLOGY, 2021, 48 (08) : 1253 - 1256
  • [33] Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency?
    Topaloglu, Oya
    Arslan, Muyesser Sayki
    Karakose, Melia
    Ucan, Bekir
    Ginis, Zeynep
    Cakir, Evrim
    Akkaymak, Esra Tutal
    Sahin, Mustafa
    Ozbek, Mustafa
    Cakal, Erman
    Delibasi, Tuncay
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (05) : 428 - 433
  • [34] Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex
    Iversen, N
    Strekerud, FG
    Abildgaard, U
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (07) : 591 - 598
  • [35] Genetic variation in the tissue factor gene is associated with clinical outcome in severe sepsis patients
    Dongwei Shi
    Zhenju Song
    Jun Yin
    Mingming Xue
    Chenling Yao
    Zhan Sun
    Mian Shao
    Zhi Deng
    Yaping Zhang
    Zhengang Tao
    Si Sun
    Jin Zhang
    Lingyu Xing
    Zhimin Dong
    Yuxin Wang
    Chaoyang Tong
    Critical Care, 18
  • [36] The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin
    Al Otair, Hadil A.
    Gader, Abdel Galil M. Abdel
    Khurshid, Syed M.
    Alzeer, Abdulaziz H.
    Al Momen, Abdul Kareem
    Al Shaikh, Mashael
    Al Gahtani, Farja
    Al Aseri, Zohair A.
    Abdelrazik, Hossam A. H.
    TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) : 112 - 118
  • [37] Tissue factor pathway inhibitor as a universal anticoagulant for use in clinical laboratory tests
    Tsuji, R
    Tatsumi, N
    Hino, M
    Nishioka, T
    Takubo, T
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (03) : 165 - 174
  • [38] Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients
    Gando, S
    Nanzaki, S
    Morimoto, Y
    Ishitani, T
    Kemmotsu, O
    CRITICAL CARE MEDICINE, 2001, 29 (02) : 262 - 266
  • [39] EFFECT OF REPEATED APROSULATE((R)) AND ENOXAPARIN((R)) ADMINISTRATION ON TISSUE FACTOR PATHWAY INHIBITOR ANTIGEN LEVELS
    JESKE, W
    HOPPENSTEADT, D
    KLAUSER, R
    KAMMEREIT, A
    ECKENBERGER, P
    HAAS, S
    WYLD, P
    FAREED, J
    BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (02) : 119 - 124
  • [40] Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery
    Sun, LB
    Utoh, J
    Kunitomo, R
    Tsurusaki, S
    Tagami, H
    Hirata, T
    Moriyama, S
    Okamoto, K
    Kitamura, N
    SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 2000, 30 (02): : 122 - 126